Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Phasebio Pharmaceuticals Inc (PHAS)  
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 48,040,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for cardiopulmonary diseases. Co.'s primary product candidate, bentracimab, is a reversal agent for the antiplatelet drug ticagrelor. Co. is developing its preclinical product candidate, PB6440, is an aldosterone synthase inhibitor being developed for treatment-resistant hypertension. Co.'s preclinical programs include: Glucagon-like peptide-2, which stimulates growth of intestinal villi, increasing their ability to absorb nutrients and C-type natriuretic peptide, which is a regulator of bone growth and can rescue defects in fibroblast growth factor 3.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 0 0 0 1,795,357
Total Sell Value $0 $0 $0 $271,150
Total People Sold 0 0 0 2
Total Sell Transactions 0 0 0 2
End Date 2024-02-08 2023-11-07 2023-05-09 2022-05-09

   
Records found: 85
  Page 2 of 4  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Sharp John P Chief Financial Officer   •       –      –    2021-08-03 4/A OE $1.68 $12,600 D/D 7,500 50,224     -
   Sharp John P Chief Financial Officer   •       –      –    2021-08-03 4 A $1.68 $12,600 D/D 7,500 50,224     -
   Arnold Susan Elizabeth VP, Preclinical and Chem   •       –      –    2021-07-12 4/A OE $1.74 $7,863 D/D 4,519 27,760     -
   Arnold Susan Elizabeth VP, Preclinical and Chem   •       –      –    2021-07-12 4 A $1.74 $7,863 D/D 4,519 27,760     -
   York Michael VP, Corporate Development   •       –      –    2021-05-20 4 A $2.80 $8,112 D/D 2,897 7,059     -
   Hanson Kristopher VP, Head of Legal   •       –      –    2021-05-20 4 A $2.80 $3,046 D/D 1,088 2,087     -
   Mow Jonathan P Chief Executive Officer   •       •      –    2021-05-20 4 A $2.80 $11,099 D/D 3,964 126,850     -
   Sharp John P Chief Financial Officer   •       –      –    2021-05-20 4 A $2.80 $3,973 D/D 1,419 42,724     -
   Burkhardt Glen VP, Human Resources   •       –      –    2021-05-20 4 S $3.29 $12,538 D/D (3,811) 0     -
   Burkhardt Glen VP, Human Resources   •       –      –    2021-05-20 4 A $2.80 $10,671 D/D 3,811 3,811     -
   Arnold Susan Elizabeth VP, Preclinical and Chem   •       –      –    2021-05-20 4 A $2.80 $14,720 D/D 5,257 23,241     -
   Harrigan Edmund Director   –       •      –    2020-12-03 4 B $4.12 $24,720 D/D 6,000 6,000 2.39     -
   Thorp Clay Director   –       •      –    2020-11-24 4 B $3.50 $7,000 D/D 2,000 22,943 2.39     -
   Thorp Clay Director   –       •      –    2020-11-23 4 B $3.67 $11,010 D/D 3,000 20,943 2.39     -
   Burkhardt Glen VP, Human Resources   •       –      –    2020-11-23 4 S $3.45 $12,065 D/D (3,497) 0     -
   Burkhardt Glen VP, Human Resources   •       –      –    2020-11-20 4 A $3.00 $10,491 D/D 3,497 3,497     -
   Sharp John P Chief Financial Officer   •       –      –    2020-11-20 4 A $3.00 $3,915 D/D 1,305 41,305     -
   York Michael VP, Corporate Development   •       –      –    2020-11-20 4 A $3.00 $7,986 D/D 2,662 4,162     -
   Ballance David James VP, Research and Sci. Affairs   •       –      –    2020-11-20 4 A $3.00 $2,757 D/D 919 8,519     -
   Hanson Kristopher VP, Head of Legal   •       –      –    2020-11-20 4 A $3.00 $2,997 D/D 999 999     -
   Arnold Susan Elizabeth VP, Preclinical and Chem   •       –      –    2020-11-20 4 A $3.00 $14,496 D/D 4,832 17,984     -
   Mow Jonathan P Chief Executive Officer   •       •      –    2020-11-20 4 A $3.00 $10,929 D/D 3,643 122,886     -
   Thorp Clay Director   –       •      –    2020-11-16 4 A $0.00 $0 I/I 10,586 15,432     -
   Thorp Clay Director   –       •      –    2020-11-16 4 A $0.00 $0 D/D 2,144 17,943     -
   Thorp Clay Director   –       •      –    2020-11-16 4 D $0.00 $0 I/I (52,397) 0     -
  85 Records found
  1  2  3  4   
  Page 2 of 4
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us